Wednesday, July 8, 2026

Drug profile · INN

cinoxacin

cinoxacin (CINOXACIN) is a bacterial dna gyrase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — cinoxacin
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.89

Quick answer

cinoxacin (CINOXACIN) is a bacterial dna gyrase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN cinoxacin
Brand CINOXACIN
Mechanism Bacterial DNA gyrase inhibitor
Target Bacterial DNA gyrase
Route ORAL
Formulation CAPSULE

Mechanism of action

Bacterial DNA gyrase inhibitor

Primary target: Bacterial DNA gyrase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. ciprofloxacin Bacterial DNA gyrase inhibitor
  2. ciprofloxacin hydrochloride Bacterial DNA gyrase inhibitor
  3. moxifloxacin hydrochloride Bacterial DNA gyrase inhibitor
  4. ofloxacin Bacterial DNA gyrase inhibitor
  5. alatrofloxacin mesylate Bacterial DNA gyrase inhibitor
  6. besifloxacin hydrochloride Bacterial DNA gyrase inhibitor

Frequently asked questions

What is cinoxacin?

cinoxacin (CINOXACIN) is a bacterial dna gyrase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for cinoxacin?

CINOXACIN is a marketed brand name for cinoxacin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of cinoxacin?

cinoxacin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.